Marked Increase in Sales of Erectile Dysfunction Medication During COVID-19
J Gen Intern Med
.
2021 Sep;36(9):2912-2914.
doi: 10.1007/s11606-021-06968-2.
Epub 2021 Jun 25.
Authors
Inmaculada Hernandez
1
,
Zeynep Gul
2
,
Walid F Gellad
3
,
Benjamin J Davies
2
Affiliations
1
Division of Clinical Pharmacy, University of California, San Diego, La Jolla, CA, USA. inhernandez@health.ucsd.edu.
2
Department of Urology, UPMC, Pittsburgh, PA, USA.
3
Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
PMID:
34170453
PMCID:
PMC8229258
DOI:
10.1007/s11606-021-06968-2
No abstract available
Publication types
Letter
Research Support, N.I.H., Extramural
MeSH terms
COVID-19*
Commerce
Erectile Dysfunction* / drug therapy
Erectile Dysfunction* / epidemiology
Humans
Male
SARS-CoV-2
Grants and funding
K01 HL142847/HL/NHLBI NIH HHS/United States
K01HL142847/HL/NHLBI NIH HHS/United States